Xenikos B.V.

Xenikos announces first patient receives T-Guard(R) for steroid-refractory acute GVHD in pivotal U.S.-based Phase 3 trial

Xenikos presents promising new data from expanded access program (EAP) using T-Guard(R) to treat steroid-refractory acute GVHD at ASH Annual Meeting

Xenikos appoints Stanley Musial as Chief Financial Officer and Chief Business Officer

Xenikos receives FDA Fast Track designation for T-Guard(R) for treating steroid-refractory acute graft-versus-host disease

Xenikos announces IND clearance by the FDA for a pivotal Phase 3 trial using T-Guard(R) for treating steroid-refractory acute GVHD

Xenikos partners with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to conduct a U.S.-based Phase 3 trial to test T-Guard(R) in acute graft-versus-host disease